Provided is a compound represented by Formula (VI) for preparing lisdexamphetamine or a salt thereof. Also provided is a method for preparing lisdexamfetamine or a salt thereof including performing reduction and debenzylation of the compound represented by Formula (VI) by hydrogenation.

##STR00001##

The present invention relates to a new process for the production of vitamin A and/or its derivatives.

Embodiments of sunscreen formulations are disclosed herein. In one example, a sunscreen formulation includes a) a physical/inorganic sunscreen active ingredient at from about 5% to about 25% on a weight/weight (w/w) basis, wherein the active ingredient generates a first sun protection factor (“SPF”) value to a sunscreen formulation; b) gadusol; and c) a plurality of ingredients configured to deliver ingredients a) and b) in the sunscreen formulation, wherein the gadusol is present in the sunscreen formulation in an amount sufficient to generate a SPF booster effect in the sunscreen formulation.

The novel water-soluble salts of cannabinoids with increased bioavailability, their preparation and uses.

Biologically active cannabidiol analogs comprising a compound of the formula ##STR00001##
wherein one of R.sub.1 or R.sub.2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R.sub.1 or R.sub.2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R.sub.1 or R.sub.2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R  (I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention relates to a highly economic process for the purification of a cannabinoid acid, more specifically THCA or CBDA, from either a crude cannabis plant material or a cell culture of said cannabis plant, using ion exchange resins. The purified cannabinoid acid obtained may then be decarboxylated to yield the corresponding cannabinoid, i.e., THC or CBD, respectively.

Described herein is a hydroformylation catalyst system and method useful for producing aldehydes from olefin substrates, without using carbon monoxide gas. The hydroformylation catalyst system includes a hydroformylation catalyst complex including a Group 9 metal complexed with a phosphine-based ligand; a syngas surrogate including formic acid and an anhydride compound, which forms carbon monoxide in situ; and hydrogen, which may derive from the syngas surrogate or not derived from the syngas surrogate. The method involves reacting the olefin substrate with a syngas surrogate in the presence of a hydroformylation catalyst complex, wherein the syngas surrogate forms carbon monoxide, and optionally hydrogen, in situ, and then isolating the aldehyde compound from a reaction mixture.

The present invention relates to a new compound and the dehydrogenation of that compound to produce retinal.

The present invention relates to the functionalisation of specific 1,3-alpha-dienes (by hydroboration). These functionalized 1,3-alpha-dienes are important intermediates in organic synthesis (especially in the synthesis of carotenoids, vitamin A and/or vitamin A derivatives).